Introduction {#s1}
============

Co-existence of several antineuronal autoantibodies is widely known in paraneoplastic and primary autoimmune disorders. Several cases of autoimmune encephalitis and a number of paraneoplastic autoantibodies have been reported in myasthenia gravis (MG), including glutamic acid decarboxylase (GAD), voltage-gated potassium channel and collapsin response-mediator protein-5 autoantibodies ([@B1], [@B2]). Here we report a case of pathologically proven subacute bulbar encephalitis and low-titer acetylcholine receptor antibodies, initially misdiagnosed as a bulbar MG.

Case-Report {#s2}
===========

A 29-years-old woman with a history of depression and cryptogenic epilepsy slowly developed progressive bulbar signs with dysarthria and dysphagia and was diagnosed with a seropositive MG due to slightly increased titer of acetylcholine receptor antibodies (0.71 nmol/l, normal \< 0.4). Despite slightly increased antinuclear antibodies (1:160) there was no clinical evidence of any concomitant rheumatologic disease. Chest CT-scan revealed no malignancies or thymus hyperplasia. Surprisingly there was no improvement under pyridostigmin and the patient was referred to our hospital. Under the assumption of MG exacerbation intravenous immunoglobulin (1 g/kg) was started. In addition to dysarthria, dysphagia and bilateral facial weakness she reported episodes of slight numbness in the pharynx and tongue. She had no double vision, yet showed moderate saccadic horizontal and vertical pursuits, atypical for MG. Because of these findings polyneuritis cranialis was discussed as a possible alternative diagnosis, however anti-ganglioside antibodies were not indicative. CSF analysis revealed a discrete lymphocytic pleocytosis with 6 cells/μl by slightly increased albumin-quotient and massive local IgM synthesis (63%). Electroneurography was normal and there was no decrement in a repetitive 3/s nerve stimulation. Repeated brain MRI revealed no abnormalities. Despite initial stabilization she developed a sudden asphyxia due to regurgitation of food and bronchospasm several days later and died due to hypoxic brain injury.

Autopsy revealed extensive hypoxic damage in all gray matter areas of the brain with neuronal necrosis and already infiltrating granulocytes. Within the brain stem, especially in midbrain and pons, perivascular lymphocytic infiltrates were seen. Immunohistochemical investigation identified these inflammatory cells as CD3-positive T cells, located perivascularly as well as within the brain parenchyma ([Figure 1](#F1){ref-type="fig"}). B cells or plasma cells were not detected. Screening for the antineuronal autoantibodies revealed positive GAD and Ma2 autoantibodies in serum. However, no thymoma or other tumors have been detected on autopsy despite of extensive examination of inner organs.

![Perivascular and brain parenchymal T-cell infiltration in the midbrain. Immunohistochemistry identified these inflammatory cells as CD3-positive T cells being located mainly perivascularly (arrows) but also invading the brain parenchyma (arrowheads) (immunohistochemistry for CD3).](fneur-10-00829-g0001){#F1}

Discussion {#s3}
==========

An autoimmune brainstem encephalitis was the core pathology in our patient initially misdiagnosed as MG. The level of AChR antibodies was very low and had to be interpreted with caution. Although an additional pathogenetic role of the AChR antibodies cannot be definitely excluded, non-responsiveness to pyridostigmin and absence of a decremental response in a repetitive stimulation make it rather unlikely. Additional clinical signs, such as saccadic pursuits and sensory deficits, even if mild, are also atypical for MG. The disruption of the blood-brain-barrier and massive intrathecal IgM production confirmed an inflammatory CNS process. Immunohistopathology revealed a T-cell mediated inflammation in brainstem, typical for a paraneoplastic encephalitis, associated with autoantibodies against intracellular antigens.

Despite positive GAD- and Ma2-antibodies no tumor has been found. Patients with anti-Ma2 antibodies often develop paraneoplastic limbic or brainstem encephalitis at a very early tumor stage, including carcinoma *in situ* ([@B3]). Interestingly, eye movement abnormalities are characteristic and have been seen in 92% of those with brainstem involvement. Anti-GAD65 autoantibodies are in many cases non-paraneoplastic, however the probability of underlying cancer (mostly thymoma, lung or breast cancer) is 7-fold higher if further antineuronal antibodies coexist ([@B4]). Yet positive antinuclear antibodies and young age of our patient support probable primary autoimmune origin. Laryngospamus, respiratory or cardiac arrest have been reported as possible reasons of sudden death in brainstem encephalitis ([@B5]).

Conclusion {#s4}
==========

We present a patient with an autoimmune brainstem encephalitis and multiple autoantibodies, mimicking a bulbar form of MG. Even if mild, atypical clinical signs including sensory and eye movement abnormalities, should raise concerns about an exclusive diagnosis of MG. Sudden unexpected death must be taken into account in patients with brainstem encephalitis, requiring prolonged monitoring during disease deterioration.
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